Overview

A Long-term Extension Study of Ustekinumab in Pediatric Participants

Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Ustekinumab